Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Rare Malignant Neoplasm × dabrafenib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1

Conditions

Melanoma 27 Neoplasms 10 Thyroid Carcinoma, Anaplastic 6 Thyroid Neoplasms 5 Brain Neoplasms 5 Multiple Myeloma 3 Glioma 3 Carcinoma, Non-Small-Cell Lung 3 Skin Neoplasms 2 Neoplasm Metastasis 2 Hematologic Neoplasms 2 Glioblastoma 2 Colorectal Neoplasms 2 Astrocytoma 2 Ameloblastoma 2 Thyroid cancer, follicular 1 Thyroid cancer, Hurthle cell 1 Thyroid Cancer, Papillary 1 Solid Tumor 1 Rare Malignant Neoplasm 1 Oligodendroglioma 1 Nonseminomatous germ cell tumor 1 Neurocytoma 1 Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation 1 Lymphoma, Non-Hodgkin 1 Lymphoma 1 Locally Advanced Thyroid Gland Carcinoma 1 Leukemia, Hairy Cell 1 Gastrointestinal Stromal Tumors 1 Ganglioneuroma 1

Interventions

trametinib 1 dabrafenib 1 Imatinib Mesylate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06119789 2025-03-26

MATRIX-Rare

Oslo University Hospital

Phase 2 Recruiting

Rare Malignant Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon ⚡